Skip to main content

and
Your search also matched 3 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Recycling lithium-ion batteries from electric vehicles

Include preview-only content
  1. Article

    Open Access

    Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study

    Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) indicated for HIV-1. DTG/3TC is approved for antiretroviral therapy (A...

    Stefan Schneider, Gary Blick, Christina Burke in Infectious Diseases and Therapy (2024)

  2. Article

    Open Access

    Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses

    Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive people with HIV-1 based on results from the pivotal G...

    Paul Benson, Jennifer Kuretski, Cynthia Donovan in Infectious Diseases and Therapy (2024)

  3. Article

    Publisher Correction: Recycling lithium-ion batteries from electric vehicles

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Gavin Harper, Roberto Sommerville, Emma Kendrick, Laura Driscoll, Peter Slater in Nature (2020)